What’s the financial overview for H. Lundbeck A/S?

H. Lundbeck A/S’s market cap stands at $0.005 trillion right now. The company’s trailing twelve-month earnings per share EPS is $0.55, with a dividend yield of 2.76%. Their next earnings report is set for January 29, 2025, and the estimated EPS for that period is $1.61. You can also check out summaries of their income statement, balance sheet, and cash flow details for a fuller picture of their financials.

How can I analyze historical data?

To analyze historical data with AI tools, apply the date range filter above the table to focus on a specific period. The table displays daily open, high, low, close prices, and volume, enabling you to spot trends and patterns. Use these insights to make informed decisions based on historical performance.

What does H. Lundbeck A/S Stock ROE tell us?

H. Lundbeck A/S stock ROE shows positive market sentiment. A higher ROE means the company’s management is doing a better job at using equity financing to drive income and growth. It’s a handy metric for comparing how a company stacks up against its competitors or the broader market.

What is per share price for H. Lundbeck A/S?

The H. Lundbeck A/S stock per share price is $4.97.

H. Lundbeck A/S

HLUBF•PNK

Healthcare

Drug Manufacturers - Specialty & Generic

$4.97

$0.38(8.28%)

H. Lundbeck A/S (HLUBF) Financial Performance & Income Statement Overview

Access detailed quarterly and annual financial reports for H. Lundbeck A/S (HLUBF), covering cash flow, earnings, and balance sheets.

Revenue Growth

10.51%

↑ 10.51%

Operating Income Growth

2.35%

↑ 2.35%

Net Income Growth

37.25%

↑ 37.25%

Operating Cash Flow Growth

-18.48%

↓ 18.48%

Operating Margin

18.10%

↑ 18.10%

Gross Margin

81.55%

↑ 81.55%

Net Profit Margin

14.82%

↑ 14.82%

ROE

14.28%

↑ 14.28%

ROIC

9.62%

↑ 9.62%

H. Lundbeck A/S (HLUBF) Income Statement & Financial Overview

View the income breakdown for H. Lundbeck A/S HLUBF across both annual and quarterly reports.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024
Revenue	$6.24B	$5.54B	$5.72B	$5.48B
Cost of Revenue	$1.08B	$1.07B	$1.09B	$1.10B
Gross Profit	$5.15B	$4.47B	$4.63B	$4.38B
Gross Profit Ratio	$0.83	$0.81	$0.81	$0.80
R&D Expenses	$1.22B	$1.12B	$1.52B	$889.00M
SG&A Expenses	$2.23B	$2.76B	$2.29B	$2.48B
Operating Expenses	$3.45B	$4.29B	$3.82B	$3.35B
Total Costs & Expenses	$4.54B	$5.36B	$4.91B	$4.45B
Interest Income	$0.00	$0.00	$0.00	$0.00
Interest Expense	$221.00M	$0.00	$79.00M	$4.00M
Depreciation & Amortization	$0.00	$0.00	$0.00	$467.00M
EBITDA	$1.70B	$739.00M	$811.00M	$1.004B
EBITDA Ratio	$0.27	$0.13	$0.14	$0.18
Operating Income	$1.70B	$177.00M	$811.00M	$1.03B
Operating Income Ratio	$0.27	$0.03	$0.14	$0.19
Other Income/Expenses (Net)	-$221.00M	$503.00M	-$79.00M	-$30.00M
Income Before Tax	$1.48B	$680.00M	$732.00M	$1.00B
Income Before Tax Ratio	$0.24	$0.12	$0.13	$0.18
Income Tax Expense	$325.00M	$90.00M	-$45.00M	$230.00M
Net Income	$1.15B	$590.00M	$777.00M	$770.00M
Net Income Ratio	$0.18	$0.11	$0.14	$0.14
EPS	$1.16	$0.60	$0.78	$0.78
Diluted EPS	$1.16	$0.60	$0.78	$0.78
Weighted Avg Shares Outstanding	$991.90M	$991.23M	$996.15M	$987.18M
Weighted Avg Shares Outstanding (Diluted)	$991.90M	$991.23M	$996.15M	$987.18M

Over the last four quarters, H. Lundbeck A/S achieved steady financial progress, growing revenue from $5.48B in Q2 2024 to $6.24B in Q1 2025. Gross profit stayed firm with margins at 83% in Q1 2025 versus 80% in Q2 2024. Operating income totaled $1.70B in Q1 2025, maintaining a 27% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $1.70B. Net income rose to $1.15B, with EPS at $1.16. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;